Head-to-head comparison of nuclear imaging approaches to quantify tumor CD8+ T-cell infiltration [0.03%]
Gerwin G W Sandker,René Raavé,Inês F Antunes et al.
Gerwin G W Sandker et al.
Introduction: Many immunotherapies focus on (re)invigorating CD8+ T cell anti-cancer responses. Different nuclear imaging techniques have been developed to measure CD8+ T cell distributions. Comprehensive comparisons of i...
Pharmacokinetics of hyaluronidase-facilitated subcutaneous immunoglobulin 10% in pediatric patients with primary immunodeficiency disease [0.03%]
用于原发性免疫缺陷病儿童患者的透明质酸酶辅助皮下注射10%免疫球蛋白的药代动力学
Zhaoyang Li,Yang Teng,Sharon Russo-Schwarzbaum et al.
Zhaoyang Li et al.
Introduction: Hyaluronidase-facilitated subcutaneous immunoglobulin 10% (fSCIG 10%) is a unique and effective treatment for primary immunodeficiency disease (PID), allowing for less frequent administration than convention...
Chimeric CD3ζ chains containing CD28 signalling motifs enhance antigen-specific IL-2 production and expansion of human TCR-engineered T cells in vitro [0.03%]
嵌合CD3ζ链中包含的CD28信号基序增强人类TCR工程T细胞体外特异性IL-2产生和扩增
Samuel J Burgess,Hans J Stauss,Emma C Morris
Samuel J Burgess
Gene-engineered T-cell products have been developed for immunotherapy to treat cancers, with great success observed in haematological malignancies but limited efficacy in treating solid cancers. TCR-engineered T cells utilize transferred TC...
Overall survival by baseline and on-treatment systemic immune-inflammation index in patients with advanced cancer receiving immune checkpoint inhibitors: a large single-centre cohort study [0.03%]
基线和免疫检查点抑制剂治疗期间的系统性免疫-炎症指数对晚期癌症患者的总生存期的影响：一项大规模单中心队列研究
Oliver John Kennedy,Rebecca Lee,Fiona Blackhall et al.
Oliver John Kennedy et al.
The Systemic Immune-Inflammation Index (SIII; neutrophils/lymphocytes × platelets) is a low-cost biomarker proposed to predict outcomes with immune checkpoint inhibitors (ICIs). This study evaluated associations of baseline and early on-tr...
Neuraminidase A controls pneumococcal recognition and fate: deficiency enhances immune sensing and intracellular survival, while treatment promotes phagocytic clearance [0.03%]
神经氨酸酶A控制肺炎链球菌的识别和命运：缺陷增强免疫感应和胞内存活，而治疗促进吞噬清除
Kristine Farmen,Georgia Yfanti,Fabienne Geers et al.
Kristine Farmen et al.
Streptococcus pneumoniae (pneumococcus) is a leading cause of bacterial meningitis worldwide and is associated with cerebrovascular complications and long-term neurological sequelae. These outcomes are largely driven by an excessive yet ine...
PD-1 inhibitor-induced rheumatic, endocrine, and sarcoidosis-like immune-related adverse events in metastatic melanoma are associated with improved survival and lower corticosteroid exposure [0.03%]
抗PD-1诱导的类风湿、内分泌和肉芽肿性疾病样的免疫相关不良事件与转移性黑色素瘤改善的生存及较低的皮质类固醇暴露相关
Maria Lindén,Hifaa Al Remawi,Anna Fager et al.
Maria Lindén et al.
Introduction: Programmed cell death protein 1 (PD-1) inhibitors improve survival in advanced melanoma but can induce immune-related adverse events (irAEs). IrAEs have been linked to better outcomes. However, it remains un...
Comprehensive spatial and immune profiling of metastatic mismatch repair-deficient colorectal cancer reveals response to immunotherapy [0.03%]
全面的空间和免疫谱分析揭示了错配修复缺陷型转移性结直肠癌对免疫疗法的反应
Ilkyu Park,Hari Kang,Se-Hee Kim et al.
Ilkyu Park et al.
Introduction: Mismatch repair-deficient (dMMR) colorectal cancers (CRCs) exhibit variable clinical responses to immune checkpoint inhibitors (ICIs) despite their high immunogenicity. ...
Targeting intratumoral regulatory T cells by CD137 aptamer-shRNA chimeras [0.03%]
利用CD137适配体-shRNA嵌合分子靶向肿瘤内调节性T细胞
Kang Yi Lee,Yu Mei,Haiyan Liu et al.
Kang Yi Lee et al.
Introduction: The cytokine CD137 (TNFRSF9, 4-1BB) is best known as a T cell costimulatory molecule. However, CD137 is also part of a negative feedback mechanism that limits T cell activation, and that is employed by regul...
Sarah Danson,Robert P Jones,Kristina Duggleby et al.
Sarah Danson et al.
Cancer vaccines offer transformative potential in oncology, especially with advances in mRNA technologies. To accelerate advances in cancer vaccine research and capitalize on its COVID-19 vaccine leadership, the UK Government has launched t...
Preclinical assessment of MAGE-A4-specific TCR-NK cells against solid tumors [0.03%]
抗实体瘤MAGE-A4特异性TCR-NK细胞的临床前评估
Margherita Boieri,Justyna Kmiecik,Maja Sandve et al.
Margherita Boieri et al.
T cell (Tc) receptor (TCR)-based cell therapies have shown clinical efficacy across many cancer types and represent an attractive strategy for targeting solid tumors. However, the immunosuppressive tumor microenvironment, downregulation of ...